- Home
- FAX vs AUTL Comparison
FAX vs AUTL Comparison
Compare FAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.45
Company Overview
Basic Information| Metric | FAX | AUTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.8M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FAX | AUTL |
|---|---|---|
| Price | $15.48 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 833.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,128,000.00 |
| Revenue This Year | N/A | $672.42 |
| Revenue Next Year | N/A | $84.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $2.33 | $1.11 |
| 52 Week High | $2.84 | $2.70 |
Technical Indicators
Market Signals| Indicator | FAX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.37 | 42.20 |
| Support Level | $15.25 | $1.33 |
| Resistance Level | $15.54 | $1.56 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 65.62 | 15.38 |
Price Performance
Historical Comparison FAX
AUTL
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.